MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Screening for SLC25A46 mutations in familial and sporadic ataxic patients

S. Efthymiou, C. Bettencourt, H. Houlden (London, United Kingdom)

Meeting: 2016 International Congress

Abstract Number: 1055

Keywords: Ataxia: Genetics

Session Information

Date: Wednesday, June 22, 2016

Session Title: Ataxia

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To identify possible mutations of the SLC25A46 gene in patients with various forms of ataxia.

Background: Members of the solute carrier family 25 (SLC25) are known to transport molecules over the mitochondrial membrane. Most of the SLC25 members are located in the inner mitochondrial membrane and transport specific substrates inside and outside of the mitochondrial matrix. Several diseases are caused by mutations in the mitochondrial carrier proteins that affect either directly oxidative phosphorylation or metabolism. SLC25A46 is a novel solute carrier with higher expression levels in CNS than in periphery. Its function is totally unknown and neither functional mutations nor correlations with disease pathogenesis in animal organisms have been reported so far.

Methods: We studied 286 unrelated cases (familial and sporadic) with an ataxic phenotype, including 95 with eye problems or optic atrophy. Using direct Sanger sequencing we performed amplified each of the 8 exons of SLC25A46. Samples were sequenced using the ABI Big Dye Terminator Sequencing Kit version 1.1 on an ABI 3730xl capillary sequencer.

Results: We detected a variant in exon 1 of SLC25A46 in a patient. Insertion of a C after 166 causes frameshift and early stop in exon 1 leading to truncation of the gene products. However, this is not a pathogenic variant and does not account for the autosomal recessive mode of transmission of ataxias. No other genetic defects were identified.

Conclusions: 1. SLC25A46 genetic defects are a very rare cause of ataxia. 2. Sanger sequencing is effective and very accurate in the analysis of small genes as in this study. Looking ahead, next generation gene panels or whole exome sequencing are becoming the most efficient diagnostic tool for heterogeneous neurodegenerative disorders such as the hereditary ataxias and will soon become the initial screening method for disease genes.

To cite this abstract in AMA style:

S. Efthymiou, C. Bettencourt, H. Houlden. Screening for SLC25A46 mutations in familial and sporadic ataxic patients [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/screening-for-slc25a46-mutations-in-familial-and-sporadic-ataxic-patients/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/screening-for-slc25a46-mutations-in-familial-and-sporadic-ataxic-patients/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley